All In Biotech

Drug Trial Radar · NCT00031096

Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne

A 12-week, Randomized, Double-blind, Multicenter Study Comparing the Clinical Efficacy and Safety of Azelaic Acid 15% Gel (SH H 655 BA) With Its Vehicle (SH H 655 PBA) in Patients With Mild to Moderate Acne.

Last checked: Nov 19, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 879 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

879

Actual

Start

Jan 2002

Primary completion

Jul 2002

Study completion Jul 2002

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
Collaborators
Bayer
First posted
Feb 22, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Comparison of efficacy and safety of Azelaic Acid 15% gel with its vehicle in male and female patients with mild to moderate acne. Qualified subjects will apply the gel to their face twice a day for a period of 12 weeks. Subjects will be required to return to the doctor's office for up to 5 visits.

Conditions

  • Acne Vulgaris

Interventions

  • Azelaic Acid Gel 15% (Finacea, BAY39-6251)Drug

    Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.

  • Vehicle gel (SH H 655 PBA)Drug

    Vehicle gel (SH H 655 PBA) applied topically two times per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The nominal and percent change in lesions counts from baseline to last available visit (end of treatment) and treatment success rates based on Investigator's assessment of mild to moderate acneTime frame: 12 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Mobile, Alabama

  • Site not named

    Boulder, Colorado

  • Site not named

    Newnan, Georgia

  • Site not named

    Shawnee Mission, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Bay Shore, New York

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Hershey, Pennsylvania

  • Site not named

    Knoxville, Tennessee

  • Site not named

    Bryan, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.